Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Factor V inhibitor with double cancer].

A Okajima, J Horii, K Nasu

    [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
    |April 1, 1989
    PubMed
    Summary

    An elderly man developed a factor V inhibitor, a rare bleeding disorder, likely due to antibiotics and cancer. Treatment with immunosuppressants and steroids successfully restored factor V levels.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Use of plasma-derived factor VIIa in a child with inhibitors of FVIII for the placement of an implantable intravenous access device.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Factor IX inhibition and epitope localization of factor IX inhibitor antibodies in haemophilia B patients with anaphylactoid reactions.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Landscape effects of a non-native grass facilitate source populations of a native generalist bug, Stenotus rubrovittatus, in a heterogeneous agricultural landscape.

    Journal of insect science (Online)·2014
    Same author

    Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

    Journal of thrombosis and haemostasis : JTH·2014
    Same author

    Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

    Journal of thrombosis and haemostasis : JTH·2014
    Same author

    Two haemophilia patients with inhibitors who became ambulatory after physiotherapy under haemostatic cover with bypassing agents.

    Haemophilia : the official journal of the World Federation of Hemophilia·2013

    Area of Science:

    • Hematology
    • Immunology
    • Oncology

    Background:

    • A factor V inhibitor is a rare autoimmune bleeding disorder.
    • Acquired inhibitors can be associated with various medical conditions and medications.

    Observation:

    • An 84-year-old male with diabetes, prostatic hypertrophy, and prostate cancer presented with purpura, leg edema, anemia, and microhematuria.
    • Coagulation studies revealed prolonged clotting time, low factor V activity (14%), and a high titer of factor V inhibitor (4.9 BU/ml), identified as IgA and IgG.
    • The patient had received recent antibiotic therapy for a urinary tract infection.

    Findings:

    • Discontinuation of antibiotics and administration of azathioprine improved prothrombin time (PT).
    • Subsequent treatment with prednisolone and antibiotics normalized PT and factor V activity.

    Related Experiment Videos

  • Autopsy confirmed prostate and descending colon cancer.

    • Implications:

    • Antibiotics, advanced age, and co-existing malignancies may trigger factor V inhibitor development.
    • Immunosuppressive therapy, including corticosteroids, can effectively manage acquired factor V inhibitors.
    • This case highlights the importance of considering acquired factor inhibitors in elderly patients with unexplained bleeding and prolonged PT.